Danaher Aktie
WKN: 866197 / ISIN: US2358511028
23.07.2020 12:12:36
|
Danaher Guides Q3 Revenue Growth Above Estimates - Quick Facts
(RTTNews) - While reporting financial results for the second quarter on Thursday, medical company Danaher Corp. (DHR) said it anticipates adjusted core revenue growth for the third quarter, including Cytiva, to be in the mid- to high-single digit range.
On average, analysts polled by Thomson Reuters expect the company to report revenue growth of 4.0 percent to $5.24 billion or the quarter.
In early April, the company had withdrawn its financial guidance for the full year 2020, due to the evolving and uncertain impact of the coronavirus (COVID-19) pandemic.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Danaher Corp.mehr Nachrichten
Analysen zu Danaher Corp.mehr Analysen
Aktien in diesem Artikel
Danaher Corp. | 167,28 | 0,25% |
|